It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Multiparametric magnetic resonance imaging (mpMRI) has become increasingly important for the clinical assessment of prostate cancer (PCa), but its interpretation is generally variable due to its relatively subjective nature. Radiomics and classification methods have shown potential for improving the accuracy and objectivity of mpMRI-based PCa assessment. However, these studies are limited to a small number of classification methods, evaluation using the AUC score only, and a non-rigorous assessment of all possible combinations of radiomics and classification methods. This paper presents a systematic and rigorous framework comprised of classification, cross-validation and statistical analyses that was developed to identify the best performing classifier for PCa risk stratification based on mpMRI-derived radiomic features derived from a sizeable cohort. This classifier performed well in an independent validation set, including performing better than PI-RADS v2 in some aspects, indicating the value of objectively interpreting mpMRI images using radiomics and classification methods for PCa risk assessment.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 University of Southern California, Department of Radiology, Los Angeles, USA (GRID:grid.42505.36) (ISNI:0000 0001 2156 6853)
2 USC Institute of Urology, Los Angeles, USA (GRID:grid.42505.36) (ISNI:0000 0001 2156 6853)
3 University of Southern California, Department of Pathology, Los Angeles, USA (GRID:grid.42505.36) (ISNI:0000 0001 2156 6853)
4 University of Southern California, Department of Radiology, Los Angeles, USA (GRID:grid.42505.36) (ISNI:0000 0001 2156 6853); USC Institute of Urology, Los Angeles, USA (GRID:grid.42505.36) (ISNI:0000 0001 2156 6853)
5 Icahn School of Medicine at Mount Sinai, Department of Genetics and Genomic Sciences and Icahn Institute for Genomics and Multiscale Biology, New York, USA (GRID:grid.59734.3c) (ISNI:0000 0001 0670 2351)